Antioxidants for the treatment of patients with severe angioproliferative pulmonary hypertension?

Antioxidants and Redox Signaling

Volumn 18, Issue 14, 2013, Pages 1810-1817

  Voelkel, Norbert F ^a   Bogaard, Harm J ^b   Husseini, Aysar Al ^a   Farkas, Laszlo ^a   Gomez Arroyo, Jose ^a   Natarajan, Ramesh ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; EXTRACELLULAR SUPEROXIDE DISMUTASE; GLUTATHIONE; HEME OXYGENASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR NRF2;

ANTIOXIDANT ACTIVITY; ANTIOXIDANT RESPONSIVE ELEMENT; HEART RIGHT VENTRICLE FAILURE; HUMAN; ICOSANOID METABOLISM; LUNG VASCULAR RESISTANCE; MESENCHYMAL STEM CELL; MITOCHONDRIAL RESPIRATION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; REVIEW; STEM CELL;

ANIMALS; ANOXIA; ANTIOXIDANTS; DISEASE MODELS, ANIMAL; HEART FAILURE; HEME OXYGENASE-1; HUMANS; HYPERTENSION, PULMONARY; LUNG; MICE; NEOVASCULARIZATION, PATHOLOGIC; OXIDATIVE STRESS; RATS; SUPEROXIDE DISMUTASE;

ANIMALIA; RATTUS;

EID: 84875941102     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2012.4828     Document Type: Review

References (55)

1. Abe K, Toba M, Alzoubi A, Ito M, Fagan KA, Cool CD, Voelkel NF, McMurtry IF, and Oka M. Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation 121: 2747-2754, 2010.
2. Ahmed MN, Zhang Y, Codipilly C, Zaghloul N, Patel D, Wolin M, and Miller EJ. EC-SOD overexpression can reverse the course of hypoxia-induced pulmonary hypertension. Mol Med 18: 38-46, 2011.
3. Archer SL, Gomberg-Maitland M, Maitland ML, Rich S, Garcia JG, and Weir EK. Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1alpha-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer. Am J Physiol Heart Circ Physiol 294: H570-H578, 2008.
4. Archer SL, Marsboom G, Kim GH, Zhang HJ, Toth PT, Svensson EC, Dyck JR, Gomberg-Maitland M, Thebaud B, Husain AN, Cipriani N, and Rehman J. Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmonary arterial hypertension: a basis for excessive cell proliferation and a new therapeutic target. Circulation 121: 2661-2671, 2010.
5. Bogaard HJ, Mizuno S, Guignabert C, Al Hussaini AA, Farkas D, Ruiter G, Kraskauskas D, Fadel E, Allegood JC, Humbert M, Vonk Noordegraaf A, Spiegel S, Farkas L, and Voelkel NF. Copper dependence of angioproliferation in pulmonary arterial hypertension in rats and humans. Am J Respir Cell Mol Biol 46: 582-591, 2012.
6. Bogaard HJ, Natarajan R, Henderson SC, Long CS, Kras-kauskas D, Smithson L, Ockaili R, McCord JM, and Voelkel NF. Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure. Circulation 120: 1951-1960, 2009.
7. Bogaard HJ, Natarajan R, Mizuno S, Abbate A, Chang PJ, Chau VQ, Hoke NN, Kraskauskas D, Kasper M, Salloum FN, and Voelkel NF. Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. Am J Respir Crit Care Med 182: 652-660, 2010.
8. Bowers R, Cool C, Murphy RC, Tuder RM, Hopken MW, Flores SC, and Voelkel NF. Oxidative stress in severe pulmonary hypertension. Am J Respir Crit Care Med 169: 764-769, 2004.
9. Chang SW, Stelzner TJ, Weil JV, and Voelkel NF. Hypoxia increases plasma glutathione disulfide in rats. Lung 167: 269-276, 1989.
10. Cloonan SM and Choi AM. Mitochondria: commanders of innate immunity and disease? Curr Opin Immunol 24: 32-40, 2012.
11. Connor KM, Subbaram S, Regan KJ, Nelson KK, Ma-zurkiewicz JE, Bartholomew PJ, Aplin AE, Tai YT, Aguirre-Ghiso J, Flores SC, and Melendez JA. Mitochondrial H2O2 regulates the angiogenic phenotype via PTEN oxidation. J Biol Chem 280: 16916-16924, 2005.
12. Demarco VG, Whaley-Connell AT, Sowers JR, Habibi J, and Dellsperger KC. Contribution of oxidative stress to pulmonary arterial hypertension. World J Cardiol 2: 316-324, 2010.
13. Dennis KE, Aschner JL, Milatovic D, Schmidt JW, Aschner M, Kaplowitz MR, Zhang Y, and Fike CD. NADPH oxidases and reactive oxygen species at different stages of chronic hypoxia-induced pulmonary hypertension in newborn piglets. Am J Physiol Lung Cell Mol Physiol 297: L596-L607, 2009.
14. Dorfmüller P, Chaumais MC, Giannakouli M, Durand-Gasselin I, Raymond N, Fadel E, Mercier O, Charlotte F, Montani D, Simonneau G, Humbert M, and Perros F. Increased oxidative stress and severe arterial remodeling induced by permanent high-flow challenge in experimental pulmonary hypertension. Respir Res 12: 119, 2011.
15. Fukai T and Ushio-Fukai M. Superoxide dismutases: role in redox signaling, vascular function, and diseases. Antioxid Redox Signal 15: 1583-1606, 2011.
16. Gems D and Partridge L. Stress-response hormesis and aging: "that which does not kill us makes us stronger". Cell Metab 7: 200-203, 2008.
17. Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 115: 500-508, 2005.
18. Gomez-Arroyo J, Mizuno S, Szczepanek K, Van Tassell BW, Natarajan R, dos Remedios C, Drake JI, Farkas L, Kras-kauskas D, Wijesinghe DS, Chalfant CE, Bigbee JW, Abbate A, Lesnefsky EJ, Bogaard HJ, and Voelkel NF. Metabolic gene remodeling and mitochondrial dysfunction in falling right ventricular hypertrophy due to pulmonary arterial hypertension. Circ Heart Failure [In press], 2012.
19. Goto J, Ishikawa K, Kawamura K, Watanabe Y, Matumoto H, Sugawara D, and Maruyama Y. Heme oxygenase-1 reduces murine monocrotaline-induced pulmonary inflammatory responses and resultant right ventricular overload. Antioxid Redox Signal 4: 563-568, 2002.
20. Hartney T, Birari R, Venkataraman S, Villegas L, Martinez M, Black SM, Stenmark KR, and Nozik-Grayck E. Xanthine oxidase-derived ROS upregulate Egr-1 via ERK1/2 in PA smooth muscle cells; model to test impact of extracellular ROS in chronic hypoxia. PLoS One 6: e27531, 2011.
21. He LS, Chang SW, and Voelkel NF. Pulmonary vascular reactivity in Fischer rats. J Appl Physiol 70: 1861-1866, 1991.
22. Heymes C, Bendall JK, Ratajczak P, Cave AC, Samuel JL, Hasenfuss G, and Shah AM. Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol 41: 2164-2171, 2003.
23. Hoshikawa Y, Ono S, Suzuki S, Tanita T, Chida M, Song C, Noda M, Tabata T, Voelkel NF, and Fujimura S. Generation of oxidative stress contributes to the development of pulmonary hypertension induced by hypoxia. J Appl Physiol 90: 1299-1306, 2001.
24. Hybertson BM, Gao B, Bose SK, and McCord JM. Oxidative stress in health and disease: the therapeutic potential of Nrf2 activation. Mol Aspects Med 32: 234-246, 2011.
25. Ide T, Tsutsui H, Kinugawa S, Utsumi H, Kang D, Hattori N, Uchida K, Arimura K, Egashira K, and Takeshita A. Mi-tochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res 85: 357-363, 1999.
26. Jin N, Packer CS, and Rhoades RA. Reactive oxygen-mediated contraction in pulmonary arterial smooth muscle: cellular mechanisms. Can J Physiol Pharmacol 69: 383-388, 1991.
27. Bogaard HJ, Mizuno S, Guignabert C, Al Hussaini AA, Farkas D, Ruiter G, Kraskauskas D, Fadel E, Allegood JC, Humbert M, Vonk Noordegraaf A, Spiegel S, Farkas L, and Voelkel NF. Copper-dependence of angioproliferation in pulmonary arterial hypertension in rats and humans. AJRCCM 46: 582-591, 2012.
28. Liang OD, Mitsialis SA, Chang MS, Vergadi E, Lee C, Aslam M, Fernandez-Gonzalez A, Liu X, Baveja R, and Kour-embanas S. Mesenchymal stromal cells expressing heme oxygenase-1 reverse pulmonary hypertension. Stem Cells 29: 99-107, 2011.
29. Masri FA, Comhair SA, Dostanic-Larson I, Kaneko FT, Dweik RA, Arroliga AC, and Erzurum SC. Deficiency of lung antioxidants in idiopathic pulmonary arterial hypertension. Clin Transl Sci 1: 99-106, 2008.
30. McMurtry IF, Davidson AB, Reeves JT, and Grover RF. Inhibition of hypoxic pulmonary vasoconstriction by calcium antagonists in isolated rat lungs. Circ Res 38: 99-104, 1976.
31. Mezzaroma E, Toldo S, Farkas D, Seropian IM, Van Tassell BW, Salloum FN, Kannan HR, Menna AC, Voelkel NF, and Abbate A. The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. Proc Natl Acad Sci USA 108: 19725-19730, 2011.
32. Minamino T, Christou H, Hsieh CM, Liu Y, Dhawan V, Abraham NG, Perrella MA, Mitsialis SA, and Kourembanas S. Targeted expression of heme oxygenase-1 prevents the pulmonary inflammatory and vascular responses to hyp-oxia. Proc Natl Acad Sci USA 98: 8798-8803, 2001.
33. Motohashi H and Yamamoto M. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol Med 10: 549-557, 2004.
34. Murdoch CE, Zhang M, Cave AC, and Shah AM. NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure. Cardiovasc Res 71: 208-215, 2006.
35. Nozik-Grayck E, Suliman HB, Majka S, Albietz J, Van Rheen Z, Roush K, and Stenmark KR. Lung EC-SOD over-expression attenuates hypoxic induction of Egr-1 and chronic hypoxic pulmonary vascular remodeling. Am J Physiol Lung Cell Mol Physiol 295: L422-L430, 2008.
36. Paddenberg R, Tiefenbach M, Faulhammer P, Goldenberg A, Gries B, Pfeil U, Lips KS, Piruat JI, Lopez-Barneo J, Scher-muly RT, Weissmann N, and Kummer W. Mitochondrial complex II is essential for hypoxia-induced pulmonary va-soconstriction of intra-but not of pre-acinar arteries. Cardi-ovasc Res 93: 702-710, 2012.
37. Paky A, Michael JR, Burke-Wolin TM, Wolin MS, and Gurtner GH. Endogenous production of superoxide by rabbit lungs: effects of hypoxia or metabolic inhibitors. J Appl Physiol 74: 2868-2874, 1993.
38. Piantadosi CA, Carraway MS, Babiker A, and Suliman HB. Heme oxygenase-1 regulates cardiac mitochondrial biogenesis via Nrf2-mediated transcriptional control of nuclear respiratory factor-1. Circ Res 103: 1232-1240, 2008.
39. Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS, Nizet V, Johnson RS, Haddad GG, and Karin M. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature 453: 807-811, 2008.
40. Rubartelli A, Gattorno M, Netea MG, and Dinarello CA. Interplay between redox status and inflammasome activation. Trends Immunol 32: 559-566, 2011.
41. Sandoval J, Bauerle O, Palomar A, Gomez A, Martinez-Guerra ML, Beltran M, and Guerrero ML. Survival in primary pulmonary hypertension. Validation of a prognostic equation. Circulation 89: 1733-1744, 1994.
42. Sano M and Fukuda K. Activation of mitochondrial biogenesis by hormesis. Circ Res 103: 1191-1193, 2008.
43. Scarpulla RC. Nucleus-encoded regulators of mitochondrial function: Integration of respiratory chain expression, nutrient sensing and metabolic stress. Biochim Biophys Acta 1819: 1088-1097, 2012.
44. Semenza GL. Hypoxia-inducible factor 1: regulator of mi-tochondrial metabolism and mediator of ischemic preconditioning. Biochim Biophys Acta 1813: 1263-1268, 2011.
45. Seta F, Rahmani M, Turner PV, and Funk CD. Pulmonary oxidative stress is increased in cyclooxygenase-2 knockdown mice with mild pulmonary hypertension induced by monocrotaline. PLoS One 6: e23439, 2011.
46. Shimoda LA, Manalo DJ, Sham JS, Semenza GL, and Sylvester JT. Partial HIF-1alpha deficiency impairs pulmonary arterial myocyte electrophysiological responses to hypoxia. Am J Physiol Lung Cell Mol Physiol 281: L202-L208, 2001.
47. Sugita T, Hyers TM, Dauber IM, Wagner WW, McMurtry IF, and Reeves JT. Lung vessel leak precedes right ventricular hypertrophy in monocrotaline-treated rats. J Appl Physiol 54: 371-374, 1983.
48. Suliman HB, Carraway MS, Ali AS, Reynolds CM, Welty-Wolf KE, and Piantadosi CA. The CO/HO system reverses inhibition of mitochondrial biogenesis and prevents murine doxorubicin cardiomyopathy. J Clin Invest 117: 3730-3741, 2007.
49. Sylvester JT. Hypoxic pulmonary vasoconstriction: a radical view. Circ Res 88: 1228-1230, 2001.
50. Tabima DM, Frizzell S, and Gladwin MT. Reactive oxygen and nitrogen species in pulmonary hypertension. Free Radic Biol Med 52: 1970-1986, 2012.
51. Tsutsui H, Kinugawa S, and Matsushima S. Oxidative stress and mitochondrial DNA damage in heart failure. Circ J 72 Suppl A: A31-A37, 2008.
52. Van Rheen Z, Fattman C, Domarski S, Majka S, Klemm D, Stenmark KR, and Nozik-Grayck E. Lung extracellular su-peroxide dismutase overexpression lessens bleomycin-induced pulmonary hypertension and vascular remodeling. Am J Respir Cell Mol Biol 44: 500-508, 2011.
53. Waypa GB, Marks JD, Mack MM, Boriboun C, Mungai PT, and Schumacker PT. Mitochondrial reactive oxygen species trigger calcium increases during hypoxia in pulmonary arterial myocytes. Circ Res 91: 719-726, 2002.
54. Yet SF, Perrella MA, Layne MD, Hsieh CM, Maemura K, Kobzik L, Wiesel P, Christou H, Kourembanas S, and Lee ME. Hypoxia induces severe right ventricular dilatation and infarction in heme oxygenase-1 null mice. J Clin Invest 103: R23-R29, 1999.
55. Zhang WH, Zhang YJ, Liu CP, Yu BX, and Lu WX. Sim-vastatin protects against the development of monocrotaline-induced pulmonary hypertension in rats via a heme oxygenase-1-dependent pathway. Exp Lung Res 37: 492-499, 2011.